Kevin D. Bunker, Chief Scientific Officer at Zentalis Pharmaceuticals, Inc. (ZNTL), sold 80,000 shares at $30.02 ($2.4M) on 2023-05-26, disclosed to the SEC on 2023-05-31.
Scheduled sale ($2.4M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ZNTL | SELL | 2022-08-12 | $150K | — | Filing → |
| ZNTL | SELL | 2022-07-20 | $150K | — | Filing → |
| ZNTL | SELL | 2022-07-14 | $300K | — | Filing → |